Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04794322 · ClinicalTrials.gov registry record
Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
A clinical trial of Ovarian Neoplasms and Fallopian Tube Neoplasms, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 250
- Enrollment target
- 6
- Study locations
NCT04794322 is a study of Ovarian Neoplasms and Fallopian Tube Neoplasms that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 250 participants, below the 361-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (31% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT04794322, a study of Ovarian Neoplasms and Fallopian Tube Neoplasms, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 250 participants
- Enrollment target
- 6
- Study locations
Study Summary
The study aims to develop a test for early detection of ovarian cancer using DNA from a growth involving the ovary found in a washing of the uterus (womb), and proteins found in the blood. The samples of the wash and the blood will be taken before surgery. After surgery, doctors will determine whether the participant had ovarian cancer or a benign disease of the ovaries. The tests of the washings and the blood will be examined to see how much the participants with ovarian cancer can be separated from the participants with a benign ovarian disease by the tests. Small amounts from the washing and the blood samples will be sent to four sites for analysis. Statistical analyses of these data will compare tumor DNA found in the washing of the uterus with proteins in the blood to detect cases of ovarian cancer. The primary goal is to find tests that are mostly positive for cases of ovarian cancer and mostly negative for patients with benign disease. It is hoped that if the tests work for participants with symptoms of the disease that these tests will also work when testing women who have no symptoms. A new study would be needed to see if the tests worked in this situation. If the tests work, this could lead to increasing the number of cases detected in early stage disease and decreasing the number of cases detected in late stage disease. If this change in late stage is large, it will likely reduce deaths due to ovarian cancer.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Uterine lavage, or a wash of the womb
- DIAGNOSTIC_TEST Blood sample
- DIAGNOSTIC_TEST Pap smear
Study Locations (6)
Maryland
- Anne Arundel Health System - Annapolis
- Johns Hopkins University School of Medicine - Baltimore
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
California
- Kaiser Permanente - San Francisco - San Francisco
Massachusetts
- Massachusetts General Hospital - Boston
Washington
- The Swedish Hospital - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2020-04-13 |
| Est. Completion | 2028-08-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04794322
The ClinicalTrials.gov registry entry for NCT04794322 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 361-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (31% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Ovarian Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which Uterine lavage, or a wash of the womb is the first listed.
NCT04794322 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Maryland, Arkansas, California.
Frequently Asked Questions
What is clinical trial NCT04794322 about?
NCT04794322 is a clinical study titled "Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer". The study aims to develop a test for early detection of ovarian cancer using DNA from a growth involving the ovary found in a washing of the uterus (womb), and proteins found in the blood. The samples of the wash and the blood will be taken before surgery. After surgery, doctors will determine wheth...
What is the current status of trial NCT04794322?
This trial is currently recruiting. The enrollment target is 250 participants. The study started on 2020-04-13. Estimated completion is 2028-08-31.
What conditions does trial NCT04794322 study?
This clinical trial studies the following conditions: Ovarian Neoplasms, Fallopian Tube Neoplasms, Stage III Ovarian Cancer AJCC v8, High Grade Ovarian Serous Adenocarcinoma, Ovarian Epithelial Carcinoma.
What interventions are being tested in trial NCT04794322?
The interventions under investigation include: Uterine lavage, or a wash of the womb (DIAGNOSTIC_TEST), Blood sample (DIAGNOSTIC_TEST), Pap smear (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04794322?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04794322 being conducted?
This trial has 6 study locations across Arkansas, California, Maryland, Massachusetts, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
RECRUITING · NA
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions
RECRUITING · NA
-
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.